Get started
Author

Vicente Alfaro

Observed names: Alfaro Vicente, Alfaro, V., V Alfaro, V. Alfaro
Institution: PharmaMar (Spain)
Observed institutions: Institució Catalana de Recerca i Estudis Avançats, Universitat Autònoma de Barcelona, Fox Chase Cancer Center, Johnson & Johnson (United States), Inserm, Université Paris-Saclay, University of Michigan, Institut Gustave Roussy, Clinical Investigation Center Plurithematic Tours, Hospices Civils de Lyon, Sarcoma Oncology Center, Centre Léon Bérard, Hôpital Lyon Sud, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, PharmaMar (Spain), Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Parc Científic de Barcelona, Universitat de Barcelona
ORCID: 0000-0002-0150-2390
Observed ORCID: 0000-0002-0150-2390
OpenAlex ID: A5048398150
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
2020 · José Trigo, Vivek Subbiah, et al. · The Lancet Oncology · 509
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
2010 · A. Poveda, I. Vergote, et al. · Annals of Oncology · 166
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
2011 · A. Gronchi, B.N. Bui, et al. · Annals of Oncology · 149
PDF
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
2012 · Axel Le Cesne, Sara Cresta, et al. · European Journal of Cancer · 145
PDF
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
2014 · Jean-Yves Blay, Michael G. Leahy, et al. · European Journal of Cancer · 123
PDF
NO and NOS isoforms in the development of apoptosis in renal ischemia/reperfusion
2005 · Jose Luis Viñas, Anna Sola, et al. · Free Radical Biology and Medicine · 89
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
2021 · Stephanie Gaillard, Ana Oaknin, et al. · Gynecologic Oncology · 70
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
2019 · Ivan Spicka, Enrique M. Ocio, et al. · Annals of Hematology · 61
PDF
A physical–chemical analysis of the acid–base response to chronic obstructive pulmonary disease
1996 · V. Alfaro, T. Torras, et al. · Canadian Journal of Physiology and Pharmacology · 51
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
2018 · Cristina Cruz, Alba Llop-Guevara, et al. · Journal of Clinical Oncology · 50
PDF
Lipocalin-2-induced renal regeneration depends on cytokines
2008 · Eugenia Vinuesa, Anna Sola, et al. · American Journal of Physiology-Renal Physiology · 50
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
2020 · Vivek Subbiah, Luis Paz-Ares, et al. · Lung Cancer · 43
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
2011 · P. Schöffski, H. Dumez, et al. · Cancer Chemotherapy and Pharmacology · 37
PDF
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
2011 · Bartomeu Massuti, Manuel Cobo, et al. · Lung Cancer · 31
Neuroprotección con memantina (antagonista no competitivo del receptor NMDA-glutamato) frente a la excitotoxicidad asociada al glutamato en la enfermedad de Alzheimer y en la demencia vascular
2006 · Adnan Tanovic, Vicente Alfaro · Revista de Neurología · 31
Lurbinectedin in the Treatment of Relapsed Small Cell Lung Cancer
2021 · Javier Baena, Andrea Modrego, et al. · Future Oncology · 29
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
2012 · Federica Grosso, Maurizio D’Incalci, et al. · Cancer Chemotherapy and Pharmacology · 29
PDF
Specification of laboratory animal use in scientific articles: Current low detail in the journals' instructions for authors and some proposals
2005 · Alfaro, V. · Methods and Findings in Experimental and Clinical Pharmacology · 29
Role of Changes in Tissular Nucleotides on the Development of Apoptosis during Ischemia/Reperfusion in Rat Small Bowel
2002 · Meritxell Genescà, Anna Sola, et al. · American Journal Of Pathology · 28
PDF
Modification of Glyceraldehyde-3-phosphate Dehydrogenase in Response to Nitric Oxide in Intestinal Preconditioning1
1999 · Anna Sola, Joan Rosell??-Catafau, et al. · Transplantation · 28
Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives
2011 · J. Sehouli, V. Alfaro, et al. · Annals of Oncology · 27
PDF
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
2011 · Claudia Lebedinsky, Javier Gómez, et al. · Cancer Chemotherapy and Pharmacology · 27
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
2009 · Bahram Forouzesh, Manuel Hidalgo, et al. · Clinical Cancer Research · 27
Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors
2010 · Quincy Chu, Alain Mita, et al. · Clinical Cancer Research · 25
Role of histamine and platelet-activating factor in allergic rhinitis
2004 · V. Alfaro · Journal of Physiology and Biochemistry · 25
Works count: 112
Citation count: 2,502
H-index: 25
I10-index: 55
Year
Topic
Type